Skip to main content

GlycoNex Incorporation (TPEX:4168)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
20.30
0.00 (0.00%)
Nov 13, 2026, 1:17 PM CST
Market Cap2.28B -4.7%
Revenue (ttm)19.51M -46.8%
Net Income-267.98M
EPS-2.40
Shares Out 112.52M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume89,410
Open20.05
Previous Close20.30
Day's Range19.90 - 20.35
52-Week Range18.30 - 30.00
Beta0.60
Analystsn/a
Price Targetn/a
Est. EarningsNov 19, 2026

About GlycoNex Incorporation

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Japan and Taiwan. The company’s pipeline under the BLA stage consists of SPD8-P, a Prolia biosimilar for the treatment of osteoporosis; and SPD8-R, a Xgeva biosimilar for the treatment of bone cancer metastases. It also develops GNX102, a humanized monoclonal antibody, which is in Phase 1 clinical trials for the treatment of various solid tumor types, such as colorectal, gastric, lung, breast, and pancr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4168
Full Company Profile

Financial Performance

In 2025, GlycoNex Incorporation's revenue was 37.86 million, an increase of 157.54% compared to the previous year's 14.70 million. Losses were -235.23 million, 2.40% more than in 2024.

Financial Statements